Prognostic roles of MAGE family�members in breast cancer based on KM‑Plotter Data

Abstract

Breast cancer is the second leading cause of cancer-associated mortality among women worldwide, and the prevalence and mortality rates associated with this disease are high in Western countries. The melanoma-associated antigen (MAGE) family proteins are well-known tumor-specific antigens; this family includes >60 proteins that serve an important part in cell cycle withdrawal, neuronal differentiation and apoptosis. The aim of the present study was to identify a biomarker within the MAGE family that is specific for breast cancer. In the present study, the prognostic role of MAGE mRNA expression was investigated in patients with breast cancer using the Kaplan-Meier plotter database. The prognostic value of MAGE members in the different intrinsic subtypes of breast cancer was further investigated, as well as the clinicopathological features of the disease. The results of the present study indicated that patients with breast cancer that had high mRNA expression levels of MAGEA5, MAGEA8, MAGEB4 and MAGEB6 had an improved relapse-free survival, whereas those with high mRNA expression levels of MAGEB18 and MAGED4 did not. These results suggested that MAGEA5, MAGEA8, MAGEB4 and MAGEB6 may have roles as tumor suppressors in the occurrence and development of breast cancer, whereas MAGEB18 and MAGED4 may possess carcinogenic potential. MAGED2, MAGED3 and MAGEF1 had different effects depending on the type of breast cancer. In particular, high MAGEC3 mRNA expression was associated with worse RFS in lymph node-positive breast cancer, but with improved RFS in lymph node-negative breast cancer. In patients with wild-type TP53 and patients with different pathological grades of breast cancer, MAGEE2, MAGEH1 and MAGEL2 were more worthy of attention as potential prognostic factors. The results of the present study may help to elucidate the role of MAGE family members in the development of breast cancer, and may promote further research that identifies MAGE-targeting reagents for the treatment of breast cancer.

Prognostic Potential of MAGEH1 and Its Correlation with Immune infiltrates in Gastric Cancer

“…2c,d). MAGEH1 expression had less in uence on ovarian cancer and as reported [19], high MAGEH1 expression had an association with inferior RFS in breast cancer (Fig. 2h).…”

“…Ojima and his colleagues highlighted the role of negativeexpressed MAGEH1 in the effectiveness of Gemcitabine therapy for biliary cancer [17]. Moreover, previous work stated that low expression of MAGEH1 could promote the progression of hepatocellular carcinoma (LISC) and serve as a marker for prognosis in its patients [18], while over-expressed MAGEH1 predicted an adverse prognosis in breast cancer [19]. These ndings suggest that MAGEH1 has an underlying impact on the progression of tumors.…”

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

“…Their reactivation during neoplastic transformation may play an important role in immunosurveillance, as MAGE proteins are antigens expressed by several malignancies [ 111 ]. Although their expression is not yet well investigated in PDAC, a recent study showed that high expression levels of MAGEB4 mRNA in breast cancer patients correlate with an improved relapse-free survival, regardless of breast cancer subtype [ 112 ]. GLI3 and MEGF8 belong to the well-known hedgehog (HH) signaling cascade, frequently altered in PDAC [ 113 ].…”

Exploration and Verification of a Six-RNA Binding Proteins-based Prognosis Evaluating Model for Hepatocellular Carcinoma

“…For preliminary validation of the expression of the hub genes in our model, we referred to the immunohistochemical results from Human Protein Atlas [38] (https://www.proteinatlas.org). Also, the Kaplan-Meier plotter [39](https://kmplot.com) was used for overall survival analysis.…”